{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:58:26Z","timestamp":1773154706330,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prostate-specific membrane antigen-positron emission tomography-(PSMA-PET) imaging facilitates dose-escalated salvage radiotherapy (DE-SRT) with simultaneous-integrated boost (SIB) for PET-positive lesions in patients with prostate cancer (PC). Therefore, we aimed to compare toxicity rates of DE-SRT with SIB to conventional SRT (C-SRT) without SIB and to report outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We evaluated 199 patients who were treated with SRT between June 2014 and June 2020. 101 patients received DE-SRT with SIB for PET-positive local recurrence and\/or PET-positive lymph nodes. 98 patients were treated with C-SRT to the prostate bed +\/\u2212 elective pelvic lymphatic pathways without SIB. All patients received PSMA-PET imaging prior to DE-SRT ([68Ga]PSMA-11: 45.5%; [18F]-labeled PSMA: 54.5%). Toxicity rates for early (&amp;lt;6 months) and late (&amp;gt;6 months) gastrointestinal (GI) toxicities rectal bleeding, proctitis, stool incontinence, and genitourinary (GU) toxicities hematuria, cystitis, urine incontinence, urinary obstruction, and erectile dysfunction were assessed. Further, we analyzed the outcome with disease-free survival (DFS) and prostate-specific antigen (PSA) response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall toxicity rates for early GI (C-SRT: 2.1%, DE-SRT: 1.0%) and late GI (C-SRT: 1.4%, DE-SRT: 5.3%) toxicities \u2265 grade 2 were similar. Early GU (C-SRT: 2.1%, DE-SRT: 3.0%) and late GU (C-SRT: 11.0%, DE-SRT: 14.7%) toxicities \u2265 grade 2 were comparable, as well. Early and late toxicity rates did not differ significantly between DE-SRT <jats:italic>versus<\/jats:italic> C-SRT in all subcategories (p&amp;gt;0.05). PSA response (PSA \u22640.2 ng\/ml) in the overall group of patients with DE-SRT was 75.0% and 86.4% at first and last follow-up, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DE-SRT showed no significantly increased toxicity rates compared with C-SRT and thus is feasible. The outcome of DE-SRT showed good results. Therefore, DE-SRT with a PSMA-PET-based SIB can be considered for the personalized treatment in patients with recurrent PC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.715020","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:27:22Z","timestamp":1627633642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Marco M. E.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Dewes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva K.","family":"Sage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Devecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin A.","family":"Eitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kilian","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00701.x","article-title":"The Management of Prostate Cancer in Patients With a Rising Prostate-Specific Antigen Level","volume":"86","author":"Fichtner","year":"2000","journal-title":"BJU Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30456-3","article-title":"Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy (TROG 08.03\/ANZUP RAVES): A Randomised, Controlled, Phase 3, Non-Inferiority Trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31553-1","article-title":"Timing of Radiotherapy After Radical Prostatectomy (RADICALS-RT): A Randomised, Controlled Phase 3 Trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30454-x","article-title":"Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Plus Short-Term Androgen Deprivation Therapy in Men With Localised Prostate Cancer After Radical Prostatectomy (GETUG-AFU 17): A Randomised, Phase 3 Trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"B6","volume-title":"Eau - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020. European Association of Urology Guidelines","author":"Mottet","year":"2020"},{"key":"B7","unstructured":"Interdisziplin\u00e4re Leitlinie Der Qualit\u00e4t S3 Zur Fr\u00fcherkennung, Diagnose Und Therapie Der Verschiedenen Stadien Des Prostatakarzinoms, Langversion 5.1, AWMF Registernummer: 043\/022ol2019"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/bc200279b","article-title":"68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjugate Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ph10040077","article-title":"Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer","volume":"10","author":"Cardinale","year":"2017","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-021-00120-5","article-title":"Automated Synthesis of [(18)F]Ga-rhPSMA-7\/-7.3: Results, Quality Control and Experience From More Than 200 Routine Productions","volume":"6","author":"Wurzer","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z","article-title":"(68)Ga-Psma PET\/CT: Joint EANM and SNMMI Procedure Guideline for Prostate Cancer Imaging: Version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.07.017","article-title":"Guidelines for Target Volume Definition in Post-Operative Radiotherapy for Prostate Cancer, on Behalf of the EORTC Radiation Oncology Group","volume":"84","author":"Poortmans","year":"2007","journal-title":"Radiother Oncol"},{"key":"B15","unstructured":"Common Terminology Criteria for Adverse Events Version 5.02017"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"Eau-Estro-Siog Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23347","article-title":"(68) Ga-PSMA-PET for Radiation Treatment Planning in Prostate Cancer Recurrences After Surgery: Individualized Medicine or New Standard in Salvage Treatment","volume":"77","author":"Habl","year":"2017","journal-title":"Prostate"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"Eau-Estro-Siog Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment With Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-Analysis of the Alpha\/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30102-4","article-title":"Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.7397","article-title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61095-7","article-title":"Combined Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced Prostate Cancer: A Randomised, Phase 3 Trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet (London England)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone\/Radiation Interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.004","article-title":"Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.06.027","article-title":"Radiotherapy for Recurrent Prostate Cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary Group","volume":"129","author":"Lieng","year":"2018","journal-title":"Radiother Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","article-title":"The Dose-Response of Salvage Radiotherapy Following Radical Prostatectomy: A Systematic Review and Meta-Analysis","volume":"121","author":"King","year":"2016","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome After PSMA PET\/CT Based Salvage Radiotherapy in Patients With Biochemical Recurrence After Radical Prostatectomy: A Bi-Institutional Retrospective Analysis","volume":"60","author":"Schmidt-Hegemann","year":"2018","journal-title":"J Nucl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13014-017-0877-x","article-title":"Intermediate-Term Outcome After PSMA-PET Guided High-Dose Radiotherapy of Recurrent High-Risk Prostate Cancer Patients","volume":"12","author":"Zschaeck","year":"2017","journal-title":"Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150579","article-title":"Intensity-Modulated Salvage Radiotherapy With Simultaneous Integrated Boost for Local Recurrence of Prostate Carcinoma: A Pilot Study on the Place of PET-choline for Guiding Target Volume Delineation","volume":"89","author":"Wahart","year":"2016","journal-title":"Br J radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13510","article-title":"Toxicity and Efficacy of Salvage Carbon 11-Choline Positron Emission Tomography\/Computed Tomography-Guided Radiation Therapy in Patients With Lymph Node Recurrence of Prostate Cancer","volume":"119","author":"Fodor","year":"2017","journal-title":"BJU Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.3529","article-title":"Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09\/10","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.012","article-title":"Higher-Than-Expected Severe (Grade 3-4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-Institution Analysis of 1176 Patients","volume":"66","author":"Cozzarini","year":"2014","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00111-x","article-title":"Salvage Radiotherapy With or Without Short-Term Hormone Therapy for Rising Prostate-Specific Antigen Concentration After Radical Prostatectomy (GETUG-AFU 16): A Randomised, Multicentre, Open-Label Phase 3 Trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.08.012","article-title":"Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Oligorecurrent Prostate Cancer Treated With Metastases-Directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation","volume":"7","author":"Kroeze","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment Outcomes From (68)Ga-PSMA PET\/CT-Informed Salvage Radiation Treatment in Men With Rising Psa After Radical Prostatectomy: Prognostic Value of a Negative Psma Pet","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year Freedom From Progression After (68)Ga-Psma PET\/CT-Triaged Management in Men With Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18f-fluciclovine-PET\/CT Imaging Versus Conventional Imaging Alone to Guide Postprostatectomy Salvage Radiotherapy for Prostate Cancer (EMPIRE-1): A Single Centre, Open-Label, Phase 2\/3 Randomised Controlled Trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000002703","article-title":"A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET\/CT","volume":"44","author":"Pernthaler","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-Pair Comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-Pair Comparison of (68)Ga-PSMA-11 and (18)F-Rhpsma-7 PET\/CT in Patients With Primary and Biochemical Recurrence of Prostate Cancer: Frequency of non-Tumor Related Uptake and Tumor Positivity","volume":"41","author":"Kroenke","year":"2020","journal-title":"J Nucl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5200-1","article-title":"Randomized Prospective Phase III Trial of 68Ga-PSMA-11 PET\/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]","volume":"19","author":"Calais","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.715020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:27:29Z","timestamp":1627633649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.715020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":42,"alternative-id":["10.3389\/fonc.2021.715020"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.715020","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"article-number":"715020"}}